Advertisement
PFE vs SNY
Which Stock Would AI Choose? Pfizer Inc. (PFE) vs. Sanofi (SNY) Stock Comparison
Key Takeaways
- Pfizer Inc. (PFE) and Sanofi (SNY) are both large-cap pharmaceutical leaders, but they sit at very different points in their growth cycles.
- PFE offers a high dividend yield and a turnaround narrative, while SNY is delivering stronger near-term revenue momentum driven by its blockbuster drug Dupixent.
- PFE faces a looming patent cliff, whereas SNY is managing Dupixent's loss of exclusivity further out, around 2031.
- Tickeron AI Verdict: Based on observable trend consistency, growth momentum, and recent guidance upgrades, Tickeron's AI currently favors SNY over PFE.
- For more context, explore PFE Major News and PFE Today's Price Move, as well as SNY Major News and SNY Today's Price Move.
- To see how automated systems are trading these and other names, explore the curated Trending AI Robots.
Introduction
Pfizer Inc. and Sanofi are two of the world's largest pharmaceutical companies, yet they present investors with contrasting risk-and-reward profiles. Pfizer, a U.S.-based drugmaker, is navigating a post-pandemic reset, cost reductions, and an approaching patent cliff. Sanofi, headquartered in France, is riding strong growth from its immunology franchise, led by Dupixent, while reshaping its pipeline for the next decade. This stock comparison is relevant for income-oriented investors, growth-focused traders, and anyone weighing relative performance and market positioning within the healthcare sector. Understanding how these two giants differ in momentum, catalysts, and risk can help clarify which name may be better suited to current market conditions.
PFE Overview and Recent Performance
PFE, or Pfizer Inc., develops and sells medicines and vaccines across oncology, cardiovascular disease, immunology, and infectious diseases. Major products include the blood thinner Eliquis, cancer treatments Padcev and Lorbrena, and COVID-related products Comirnaty and Paxlovid. In recent market activity, Pfizer shares have staged a notable recovery, climbing roughly 20% year to date and touching a 52-week high, supported by a dividend yield near 5.8%.
Sentiment has been shaped by a mix of factors. Management has highlighted progress in cost-cutting, with additional savings targeted through 2029, and growth from newly acquired products, including those tied to the Seagen, Biohaven, and Metsera deals. However, recent quarters have also included non-cash write-downs and declining COVID product sales, and investors remain focused on upcoming patent expirations for drugs such as Eliquis and Ibrance. The result is a stock that trades at a low valuation but carries meaningful execution risk.
SNY Overview and Recent Performance
SNY, or Sanofi, is a Paris-based pharmaceutical company concentrated on immunology, rare diseases, and vaccines. Its flagship product, Dupixent, co-developed with Regeneron, treats inflammatory conditions such as eczema and asthma. In recent weeks, Sanofi has delivered double-digit sales growth, with Dupixent sales rising roughly 35% and the company raising its full-year guidance on strong commercial momentum.
Sanofi's recent performance has been driven by new medicines and disciplined cost management, and shares rallied after the company signaled openness to larger acquisitions to build its next growth phase. New CEO Belén Garijo has prioritized protecting earnings through Dupixent's eventual loss of exclusivity, which is not expected until around 2031. This gives Sanofi a longer runway than some peers, though the stock's valuation reflects a higher multiple and its own execution challenges in the vaccine segment.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's most suitable automated trading bots for current market conditions. While Tickeron offers hundreds of AI trading bots that trade thousands of different tickers, only a portion earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and set of tickers it trades, allowing users to evaluate them across different risk and return profiles. For traders comparing names like PFE and SNY, these tools provide an alternative, data-driven lens on market positioning. Explore the Trending AI Robots to see which strategies are currently standing out.
Head-to-Head Comparison
The clearest contrast between these two stocks is momentum versus income. SNY is delivering stronger top-line growth, led by Dupixent, and has been upgrading its outlook. PFE, by contrast, is leaning on cost discipline, a high dividend yield, and a diversified oncology franchise to offset a patent cliff that arrives sooner than Sanofi's.
On valuation, PFE trades at a lower multiple and offers a yield near 5.8%, appealing to income investors. SNY carries a higher multiple and a lower yield, reflecting its stronger growth profile. Risk factors also differ: Pfizer faces near-term earnings pressure from patent expirations and write-downs, while Sanofi must manage concentration risk around Dupixent and softer vaccine sales. Sector exposure is similar, but the market sentiment around each name has diverged, favoring the company showing consistent earnings upgrades.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue momentum, and the direction of guidance revisions, Tickeron's AI currently leans toward SNY over PFE. Sanofi's recent double-digit sales growth, upward guidance revisions, and longer runway before its key patent expires suggest a steadier near-term trend. Pfizer's high dividend and low valuation remain attractive attributes, but its nearer-term patent cliff and recent write-downs introduce greater uncertainty. This assessment is probabilistic rather than definitive and reflects current market positioning rather than a fixed recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PFE is a Hold and SNY is a Buy.
PFE's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 instances where the indicator moved out of the overbought zone. In 16 of the 25 cases the stock moved lower in the days that followed. This puts the odds of a move down at 64%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 58 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 47 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for PFE turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 25 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Bullish Trend Analysis
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 86 of 194 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.966) is normal, around the industry mean (-1.421). P/E Ratio (38.169) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.059) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
SNY in upward trend: 10-day moving average broke above 50-day moving average on November 02, 2026
The 10-day moving average for SNY crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on SNY as a result. In 56 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for SNY just turned positive on October 15, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in 21 of 46 cases over the following month. The odds of a continued upward trend are 46%.
SNY moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 154 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SNY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SNY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. SNY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock slightly worse than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.629) is normal, around the industry mean (-1.421). P/E Ratio (28.596) is within average values for comparable stocks, (21.700). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.169) is considerably higher than the industry average of (0.038). P/S Ratio (1.829) is also within normal values, averaging (4.033).
PFE | SNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 90 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 63 | |
SMR RATING 1..100 | 83 | 81 | |
PRICE GROWTH RATING 1..100 | 27 | 41 | |
P/E GROWTH RATING 1..100 | 4 | 7 | |
SEASONALITY SCORE 1..100 | 48 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNY's Valuation (88) in the Pharmaceuticals Major industry is in the same range as PFE (96). This means that SNY’s stock grew similarly to PFE’s over the last 12 months.
SNY's Profit vs Risk Rating (63) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (100). This means that SNY’s stock grew somewhat faster than PFE’s over the last 12 months.
SNY's SMR Rating (81) in the Pharmaceuticals Major industry is in the same range as PFE (83). This means that SNY’s stock grew similarly to PFE’s over the last 12 months.
PFE's Price Growth Rating (27) in the Pharmaceuticals Major industry is in the same range as SNY (41). This means that PFE’s stock grew similarly to SNY’s over the last 12 months.
PFE's P/E Growth Rating (4) in the Pharmaceuticals Major industry is in the same range as SNY (7). This means that PFE’s stock grew similarly to SNY’s over the last 12 months.
| PFE | SNY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 64% | 1 day ago 45% |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 47% |
| Momentum ODDS (%) | 1 day ago 53% | 1 day ago 57% |
| MACD ODDS (%) | 1 day ago 57% | 1 day ago 46% |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 53% |
| TrendMonth ODDS (%) | 1 day ago 48% | 1 day ago 49% |
| Advances ODDS (%) | 8 days ago 54% | 1 day ago 51% |
| Declines ODDS (%) | 1 day ago 56% | 28 days ago 52% |
| BollingerBands ODDS (%) | N/A | 1 day ago 50% |
| Aroon ODDS (%) | 1 day ago 44% | 1 day ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PFE’s FA Score shows that 2 FA rating(s) are green while SNY’s FA Score has 1 green FA rating(s).
- PFE’s FA Score: 2 green, 3 red.
- SNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PFE’s TA Score shows that 2 TA indicator(s) are bullish while SNY’s TA Score has 5 bullish TA indicator(s).
- PFE’s TA Score: 2 bullish, 5 bearish.
- SNY’s TA Score: 5 bullish, 5 bearish.
Price Growth
PFE (@Pharmaceuticals: Major) experienced а -2.30% price change this week, while SNY (@Pharmaceuticals: Major) price change was +6.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.88%. For the same industry, the average monthly price growth was +1.80%, and the average quarterly price growth was +5.50%.
Reported Earning Dates
PFE is expected to report earnings on Feb 02, 2027.
SNY is expected to report earnings on Jan 29, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+0.88% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.54% | ||
| BMY - PFE | 60% Loosely correlated | N/A | ||
| AMGN - PFE | 53% Loosely correlated | +1.04% | ||
| GSK - PFE | 51% Loosely correlated | +2.40% | ||
| NVS - PFE | 50% Loosely correlated | +0.70% | ||
| BIIB - PFE | 46% Loosely correlated | +2.63% | ||
More | ||||
SNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with PFE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To SNY | 1D Price Change % | ||
|---|---|---|---|---|
| SNY | 100% | +2.30% | ||
| PFE - SNY | 47% Loosely correlated | -0.54% | ||
| JNJ - SNY | 36% Loosely correlated | +2.13% | ||
| MRK - SNY | 35% Loosely correlated | +1.38% | ||
| AMGN - SNY | 35% Loosely correlated | +1.04% | ||
| GILD - SNY | 34% Loosely correlated | +1.46% | ||
More | ||||